Copyright
©The Author(s) 2025.
World J Clin Cases. Jul 26, 2025; 13(21): 104723
Published online Jul 26, 2025. doi: 10.12998/wjcc.v13.i21.104723
Published online Jul 26, 2025. doi: 10.12998/wjcc.v13.i21.104723
Table 1 Conditions associated with high serum basal tryptase levels
Etiology | Diagnostic methods | Serum basal tryptase range | Incidence |
Hereditary alpha tryptasemia | ddPCR | 8-50 ng/mL | ≤ 67% |
No disease is detected | Exclusion diagnosis | Variable | ≤ 23% |
Renal failure | Glomerular filtration rate < 60 mL/minute, elevated creatinine | 10-50 ng/mL | ≤ 16% |
Systemic mastocytosis | Bone marrow aspiration, c-KIT D816V mutation by ddPCR, skin biopsy | 20-200 ng/mL | ≤ 5% |
Other myeloid neoplasms, acute myeloid leukemia, myeloproliferative neoplasms, myeloid neoplasms with eosinophilia, myelodysplastic neoplasms | Complete blood count, bone marrow aspiration, molecular genetics, cytogenetics | 15-50 ng/mL | Rare |
Hypereosinophilic syndrome | Bone marrow aspiration, molecular genetics, cytogenetics | 10-50 ng/mL | Rare |
Chronic inflammatory diseases, rheumatoid arthritis, eosinophilic esophagitis | Rheumatological examinations, endoscopy, biopsy | 5-25 ng/mL | Rare |
Table 2 Clinical findings in hereditary alpha tryptasemia
Clinical findings | |
Gastrointestinal symptoms | Nausea |
Abdominal pain | |
Diarrhea | |
Vomiting | |
Dyspepsia | |
Neuropsychiatric findings | Cognitive disorders (such as memory disorders) |
Fatigue | |
Sleep disorders | |
Depressive disorders | |
Nervousness | |
Cutaneous and allergic symptoms | Sudden hot flushes |
Pruritus | |
Rash, urticaria | |
Pain | Muscle pain |
Headache | |
Joint pain | |
Other findings | Systemic sudden hypersensitivity reaction |
Joint hypermobility |
Table 3 Common indications for genetic testing for hereditary alpha tryptasemia
sBT level ≥ 8 ng/mL |
Recurrent signs of MC activation with unclear etiology (such as idiopathic anaphylaxis) |
Suspected SM with negative c-KIT D816V, but very high TPS level |
SM or MCAS with severe mediator-related symptoms |
Serum TPS value > 15.0 ng/mL without underlying mastocytosis or myeloid neoplasm |
Familial clustering of systemic MC activation symptoms |
Higher levels of sBT according to the degree of bone marrow mast cell infiltration |
Diagnosed or suspected idiopathic or secondary MCAS |
- Citation: Tüsüz Önata E, Özdemir Ö, Savaşan S. Hereditary alpha tryptasemia and clinical implications. World J Clin Cases 2025; 13(21): 104723
- URL: https://www.wjgnet.com/2307-8960/full/v13/i21/104723.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v13.i21.104723